Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 12 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Rush University Medical Center has 10 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 10 examiners across 10 art units, indicating a fully distributed prosecution workload with no reported overlap in examiner or technical assignment.
RILEY, JEZIA is the busiest examiner, with 1 pending matter. Because the examiner workload is distributed, counsel should prioritize centralized docket control and consistent portfolio review while preparing responses independently for each art-unit context.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (25%) |
| §103 only | 2 (17%) |
| Multi-statute (no §101) | 7 (58%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GILLIGAN, CHRISTOPHER L | 1 | 57.5% | +40.3% |
| RILEY, JEZIA | 1 | 83.0% | +7.2% |
| LY, KRISTINA ELISABETH | 1 | 37.5% | +100.0% |
| BRADLEY, CHRISTINA | 1 | 62.6% | +33.3% |
| JAVANMARD, SAHAR | 1 | 64.9% | +34.1% |
| PHILIPS, BRADLEY H | 1 | 67.5% | +30.9% |
| UHLIR, CHRISTOPHER J | 1 | 61.9% | +10.0% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.4% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17029113 | Focal Pressure Applicator to Cease Bleeding | COLELLO, ERIN L | 181d overdue |
| 17640698 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISORDERS | COPPINS, JANET L | 58d overdue |
| 17767620 | MODULATING INTERLEUKIN-10 SIGNALING TO BOOST HEALING IN DIABETIC WOUNDS | ALLEN, MARIANNE P | 20d |
| 17441029 | METHOD OF TREATING DISEASE USING A VECTOR ENCODING TPP1 | WILSON, MICHAEL C | 61d |
| 19102061 | SYSTEMS AND METHODS TO ENHANCE HEALTHCARE COMMUNICATIONS | GILLIGAN, CHRISTOPHER L | — |
| 18886734 | SEQUENTIAL STAINING FOR MULTIPLEX ANALYSES OF TISSUES AND CELLS | RILEY, JEZIA | — |
| 18587523 | Role of Human Pegivirus (HPGV) in Parkinson's Disease: Implications for Diagnosis and Treatment | LY, KRISTINA ELISABETH | — |
| 18550859 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS WITH INTRANASAL NF-KAPPAB ESSENTIAL MODIFIER (NEMO)-BINDING DOMAIN (NBD) PEPTIDE | BRADLEY, CHRISTINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17640698 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISORDERS | COPPINS, JANET L | 58d overdue |
| 17767620 | MODULATING INTERLEUKIN-10 SIGNALING TO BOOST HEALING IN DIABETIC WOUNDS | ALLEN, MARIANNE P | 20d |
| 17441029 | METHOD OF TREATING DISEASE USING A VECTOR ENCODING TPP1 | WILSON, MICHAEL C | 61d |
| 19102061 | SYSTEMS AND METHODS TO ENHANCE HEALTHCARE COMMUNICATIONS | GILLIGAN, CHRISTOPHER L | — |
| 18587523 | Role of Human Pegivirus (HPGV) in Parkinson's Disease: Implications for Diagnosis and Treatment | LY, KRISTINA ELISABETH | — |
| 18550859 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS WITH INTRANASAL NF-KAPPAB ESSENTIAL MODIFIER (NEMO)-BINDING DOMAIN (NBD) PEPTIDE | BRADLEY, CHRISTINA | — |
| 18257817 | ADMINISTRATION OF GLYCEROL TRIBENZOATE AND GLYCEROL PHENYLBUTYRATE FOR TREATMENT OF NEURODEGENERATIVE AND UREA CYCLE DISORDERS | JAVANMARD, SAHAR | — |
| 18209867 | AUTOMATIC OXYGEN TITRATION SYSTEM AND METHOD BASED ON TARGETED OXYGEN SATURATION DURING HIGH FLOW AND LOW FLOW OXYGEN THERAPY | PHILIPS, BRADLEY H | — |
| Art Unit | Apps |
|---|---|
| 3683 | 1 |
| 1681 | 1 |
| 1671 | 1 |
| 1654 | 1 |
| 1622 | 1 |
| 3799 | 1 |
| 3619 | 1 |
| 1647 | 1 |
| 1628 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19102061 | SYSTEMS AND METHODS TO ENHANCE HEALTHCARE COMMUNICATIONS | GILLIGAN, CHRISTOPHER L | 3683 | §101§102 | Non-Final OA | — | Pending | Feb 07, 2025 |
| 18886734 | SEQUENTIAL STAINING FOR MULTIPLEX ANALYSES OF TISSUES AND CELLS | RILEY, JEZIA | 1681 | §102§103§112Other | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18587523 | Role of Human Pegivirus (HPGV) in Parkinson's Disease: Implications for Diagnosis and Treatment | LY, KRISTINA ELISABETH | 1671 | §101§102§112 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18550859 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS WITH INTRANASAL NF-KAPPAB ESSENTIAL MODIFIER (NEMO)-BINDING DOMAIN (NBD) PEPTIDE | BRADLEY, CHRISTINA | 1654 | §101§102 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18257817 | ADMINISTRATION OF GLYCEROL TRIBENZOATE AND GLYCEROL PHENYLBUTYRATE FOR TREATMENT OF NEURODEGENERATIVE AND UREA CYCLE DISORDERS | JAVANMARD, SAHAR | 1622 | §103 | Final Rejection | — | Pending | Jun 15, 2023 |
| 18209867 | AUTOMATIC OXYGEN TITRATION SYSTEM AND METHOD BASED ON TARGETED OXYGEN SATURATION DURING HIGH FLOW AND LOW FLOW OXYGEN THERAPY | PHILIPS, BRADLEY H | 3799 | §102§103§112 | Final Rejection | — | Pending | Jun 14, 2023 |
| 18131849 | SYSTEM AND TECHNIQUES FOR PROVIDING CONTINUOUS AUDITORY FEEDBACK FOR PERFORMANCE-BASED ACTIVITY | UHLIR, CHRISTOPHER J | 3619 | §103§112 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 17767620 | MODULATING INTERLEUKIN-10 SIGNALING TO BOOST HEALING IN DIABETIC WOUNDS | ALLEN, MARIANNE P | 1647 | §103§112 | Non-Final OA | 20d | Pending | Apr 08, 2022 |
| 17640698 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISORDERS | COPPINS, JANET L | 1628 | §103§112 | Non-Final OA | 58d overdue | Pending | Mar 04, 2022 |
| 17441029 | METHOD OF TREATING DISEASE USING A VECTOR ENCODING TPP1 | WILSON, MICHAEL C | 1638 | §103§112 | Non-Final OA | 61d | Pending | Sep 20, 2021 |
| 17258248 | Use of Immunomodulators to Control Infection and Stimulate Healing in Normal and Diabetic Wounds | BENAVIDES, JENNIFER ANN | 1675 | §103 | Final Rejection | — | Pending | Jan 06, 2021 |
| 17029113 | Focal Pressure Applicator to Cease Bleeding | COLELLO, ERIN L | 3771 | §102§103§112 | Non-Final OA | 181d overdue | Pending | Sep 23, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRush University Medical Center has 12 pending office actions as of October 2026, spread across 12 art units and 12 examiners.
Christopher L Gilligan has the most, with 1 of Rush University Medical Center's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
